文献速递浆细胞疾病

多发性骨髓瘤中,复发时观察到的高危继发性遗传事件在诊断时已存在于微小、不可检测的亚克隆群体中

In Multiple Myeloma, High-Risk Secondary Genetic Events Observed at Relapse Are Present From Diagnosis in Tiny, Undetectable Subclonal Populations.
PubMed 文献 · J Clin Oncol · 2022-11-07

该研究采用单细胞拷贝数异常测序分析81例浆细胞疾病患者,发现74例(91%)存在2-16个亚克隆,28.7%的患者在诊断时即携带高危亚克隆(del(17p)、del(1p32)、1q gain)。回顾性数据库显示1q gain频率从诊断时30.2%升至复发时43.6%(OR 1.78,95%CI 1.58-2.00),且诊断时即有1q gain与复发时看似获得1q gain的患者无进展生存和总生存曲线重叠,提示许多1q gain在诊断时已存在于大块分析漏检的微小亚克隆中。

要点

  • 单细胞测序分析81例患者52,176个骨髓瘤细胞,74例(91%)检出2-16个亚克隆。
  • 28.7%的患者在诊断时即存在高危亚克隆(del(17p)、del(1p32)、1q gain)。
  • 1q gain频率从诊断时30.2%升至复发时43.6%(OR 1.78,95%CI 1.58-2.00)。

核心结论

  • 数据提示识别这些稀有的侵袭性细胞可能需要早在诊断时即采取更积极的治疗,以防止其成为优势克隆。

研究设计与样本

  • 采用单细胞拷贝数异常测序分析81例浆细胞疾病患者,其中66例为诊断时、9例为首次复发、6例为症状前阶段。
  • 回顾性识别956例新诊断多发性骨髓瘤患者和首次复发患者,利用所需细胞遗传学数据评估拷贝数异常风险事件的富集及生存影响。

主要发现

  • 共分析52,176个骨髓瘤细胞,74例患者(91%)具有2-16个亚克隆。
  • 28.7%的患者在诊断时具有高危特征亚克隆(del(17p)、del(1p32)和1q gain)。
  • 一例诊断时具有亚克隆1q gain的患者,诊断、诱导后和首次复发样本中高危1q gain亚克隆比例分别为16%、70%和92%。
  • 临床数据库中1q gain频率从诊断时30.2%升至复发时43.6%(比值比1.78;95%CI 1.58-2.00)。
  • 诊断时即有1q gain的患者与复发时看似获得1q gain的患者,无进展生存和总生存曲线重叠。

关键数值与推荐

  • 高危亚克隆定义为del(17p)、del(1p32)和1q gain。
  • 1q gain频率从诊断时30.2%升至复发时43.6%(比值比1.78;95%CI 1.58-2.00)。
  • 74例患者(91%)具有2-16个亚克隆,28.7%的患者在诊断时具有高危特征亚克隆。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Multiple myeloma (MM) is characterized by copy number abnormalities (CNAs), some of which influence patient outcomes and are sometimes observed only at relapse(s), suggesting their acquisition during tumor evolution. However, the presence of micro-subclones may be missed in bulk analyses. Here, we use single-cell genomics to determine how often these high-risk events are missed at diagnosis and selected at relapse. MATERIALS AND METHODS: We analyzed 81 patients with plasma cell dyscrasias using single-cell CNA sequencing. Sixty-six patients were selected at diagnosis, nine at first relapse, and six in presymptomatic stages. A total of 956 newly diagnosed patients with MM and patients with first relapse MM have been identified retrospectively with required cytogenetic data to evaluate enrichment of CNA risk events and survival impact. RESULTS: A total of 52,176 MM cells were analyzed. Seventy-four patients (91%) had 2-16 subclones. Among these patients, 28.7% had a subclone with high-risk features (del(17p), del(1p32), and 1q gain) at diagnosis. In a patient with a subclonal 1q gain at diagnosis, we analyzed the diagnosis, postinduction, and first relapse samples, which showed a rise of the high-risk 1q gain subclone (16%, 70%, and 92%, respectively). In our clinical database, we found that the 1q gain frequency increased from 30.2% at diagnosis to 43.6% at relapse (odds ratio, 1.78; 95% CI, 1.58 to 2.00). We subsequently performed survival analyses, which showed that the progression-free and overall survival curves were superimposable between patients who had the 1q gain from diagnosis and those who seemingly acquired it at relapse. This strongly suggests that many patients had 1q gains at diagnosis in microclones that were missed by bulk analyses. CONCLUSION: These data suggest that identifying these scarce aggressive cells may necessitate more aggressive treatment as early as diagnosis to prevent them from becoming the dominant clone.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Lannes R, Samur M, Perrot A, et al. In Multiple Myeloma, High-Risk Secondary Genetic Events Observed at Relapse Are Present From Diagnosis in Tiny, Undetectable Subclonal Populations. J Clin Oncol. 2022. PMID: 36343306. doi:10.1200/JCO.21.01987

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。